Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up

Booster doses for the ongoing COVID-19 pandemic are under consideration in many countries. We report a three-month follow-up of 700 participants in a fourth vaccine dose study, comparing BNT162b2 and mRNA1273, administered four months after a third BNT162b2 dose. The primary outcomes are the levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Canetti, Michal, Barda, Noam, Gilboa, Mayan, Indenbaum, Victoria, Mandelboim, Michal, Gonen, Tal, Asraf, Keren, Weiss-Ottolenghi, Yael, Amit, Sharon, Doolman, Ram, Mendelson, Ella, Harats, Dror, Freedman, Laurence S., Kreiss, Yitshak, Lustig, Yaniv, Regev-Yochay, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745767/
https://www.ncbi.nlm.nih.gov/pubmed/36513665
http://dx.doi.org/10.1038/s41467-022-35480-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745767/
https://www.ncbi.nlm.nih.gov/pubmed/36513665
http://dx.doi.org/10.1038/s41467-022-35480-2

Ejemplares similares